Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

SELL
$0.41 - $0.86 $2,912 - $6,109
-7,104 Reduced 49.66%
7,201 $6,000
Q3 2023

Nov 14, 2023

SELL
$0.38 - $0.72 $26 - $49
-69 Reduced 0.48%
14,305 $6,000
Q2 2023

Aug 14, 2023

BUY
$0.54 - $0.95 $1,104 - $1,942
2,045 Added 16.59%
14,374 $8,000
Q1 2023

May 09, 2023

BUY
$0.9 - $1.34 $6,276 - $9,345
6,974 Added 130.23%
12,329 $12,000
Q4 2022

Feb 10, 2023

SELL
$0.85 - $16.65 $3,754 - $73,543
-4,417 Reduced 45.2%
5,355 $6,000
Q3 2022

Nov 10, 2022

BUY
$1.15 - $17.4 $6,430 - $97,300
5,592 Added 133.78%
9,772 $10,000
Q2 2022

Aug 15, 2022

SELL
$1.19 - $2.0 $13 - $22
-11 Reduced 0.26%
4,180 $6,000
Q1 2022

May 12, 2022

BUY
$1.23 - $1.9 $5,154 - $7,962
4,191 New
4,191 $7,000
Q4 2021

Feb 14, 2022

SELL
$1.64 - $2.83 $65 - $113
-40 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$2.7 - $3.59 $6,677 - $8,878
-2,473 Reduced 98.41%
40 $0
Q2 2021

Aug 16, 2021

BUY
$3.21 - $4.06 $8,066 - $10,202
2,513 New
2,513 $9,000

Others Institutions Holding MBRX

About Moleculin Biotech, Inc.


  • Ticker MBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,606,700
  • Market Cap $48.6M
  • Description
  • Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs....
More about MBRX
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.